Executive Summary
Deepak “Dee” Khuntia, M.D., currently serves as the Senior Vice President, Chief Medical Officer, and Vice President of Medical Affairs at Varian Medical Systems, a Siemens Healthineers company. He has held leadership roles at Varian since his appointment as Vice President of Medical Affairs in 2013 and is a board-certified radiation oncologist with a distinguished career spanning academic medicine, private practice, and industry sectors. Khuntia brings profound expertise in radiation oncology, with specializations in brain tumors, head and neck cancer, and lung cancer.
Professional Role and Responsibilities
- Senior Leadership: Dee Khuntia holds a triad of critical executive roles at Varian:
- Senior Vice President
- Chief Medical Officer (CMO)
- Vice President, Medical Affairs
- Medical Affairs Leadership: Since joining Varian in 2013, he leads the Office of Medical Affairs, which provides medical-clinical expertise supporting product development, regulatory pathways, clinical trials, and medical strategy.
- Industry and Innovation Influence:
- Oversaw pivotal clinical trials such as the FAST-01 and FAST-02 trials investigating innovative radiation therapy technologies, including FLASH radiotherapy and non-invasive cardiac interventional oncology treatments.
- Instrumental in guiding Varian's investigational device exemptions (IDEs) enabling early-stage evaluation of cutting-edge oncology treatment options.
- Board Membership:
- As of April 2024, Khuntia joined the board of directors at TAE Life Sciences, validating advancements in Boron Neutron Capture Therapy (BNCT) and reinforcing his role as an opinion leader in radiation oncology innovation.
Educational Background and Clinical Expertise
- Education:
- Undergraduate and Medical degrees from the University of Illinois at Chicago
- Completed residency in Radiation Oncology at the University of Illinois Medical Center
- Clinical Expertise: Recognized as an expert in treating:
- Brain tumors
- Head and neck cancers
- Lung cancer
- Research and Publications:
- Authored and co-authored over 100 peer-reviewed scientific articles, book chapters, and abstracts, with numerous citations in prominent journals such as the Journal of Clinical Oncology and Radiation Oncology.
- Significant contributions to studies on hippocampal avoidance during whole-brain radiotherapy, stereotactic radiosurgery, and advanced radiation therapy techniques.
- Participated in long-term outcome studies linking radiation treatment protocols with cognitive toxicity and quality of life post-therapy.
Industry Contributions and Thought Leadership
- Academic and Industry Integration:
Dr. Khuntia has integrated academic insight with industry leadership, including clinical trial design and medical advisory roles for Varian’s product strategies.
- Clinical Trial Leadership:
Featured prominently in clinical trials such as:
- NRG Oncology CC001 (hippocampal avoidance WBRT plus memantine)
- Studies evaluating novel radiation delivery techniques like proton FLASH radiotherapy for metastatic lesions.
- Speaking Engagements and Professional Recognition:
- FASTRO (Fellow of the American Society for Radiation Oncology) designation reflects his professional standing and peer recognition.
- Regular contributor to scientific conferences, including the American Society for Radiation Oncology (ASTRO) Annual Meetings.
- Interviewed extensively in radiation oncology history series and cited as a leader in modern radiation therapy advances.
- Innovative Technology Advocacy:
- Advocates for the adoption of MRI-guided radiation therapy as a transformative advancement in treatment precision.
- Co-author on patents and research protocols supporting FLASH radiotherapy and oncologic information systems.
Professional Network and Affiliations
- Holds active positions in professional oncology and radiation societies.
- Maintains collaborative ties with research consortia such as NRG Oncology and clinical trial groups focused on brain tumors and interventional oncology.
Actionable Insights
Dr. Dee Khuntia represents a critical executive with comprehensive authority bridging clinical expertise and corporate strategy in oncology therapeutics at Varian. His leadership spans multiple facets:
- Driving clinical validation and regulatory approval of novel radiation oncology technologies.
- Steering company medical affairs with a patient-centric, evidence-based approach.
- Serving on boards that influence next-generation cancer treatment modalities beyond standard radiotherapy.
- Direct involvement in clinical trials demonstrating Varian’s commitment to innovation and evidence generation.
Engagement efforts focusing on alignment with his strategic priorities in clinical innovation, evidence-based medicine, and oncology product development could be pivotal in advancing partnerships or collaborations within the medical technology and radiation oncology marketplace.
References and Source Highlights
- Varian Medical Systems Leadership and Press Releases (2013–2024)
- American Society for Radiation Oncology (ASTRO) Interviews and Publications (2023)
- Clinical trials and peer-reviewed journals: Journal of Clinical Oncology, Radiation Oncology, PMC articles
- TAE Life Sciences Board Appointment Announcement (April 2024)
- Industry Symposiums and Scientific Conferences Abstracts (SEMI 2022, ASTRO 2024)
LinkedIn: https://linkedin.com/in/dee-khuntia
Company: Varian Medical Systems, Palo Alto, CA (a Siemens Healthineers company)
